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ABSTRACT 
Background: Morbidity and mortality of HIV/AIDS infections is still high and as 
a global health problem particularly in Low-Middle Income Countries (LMICs). 
Indonesia ranks third in Asia Pacific in increasing HIV infection. A Study on risk 
factors for mortality in HIV/AIDS patients in Dr. Kariadi General Hospital has never 
been conducted. 
Objective: This study analyzed the risk factors for mortality among HIV/AIDS 
patients. 
Methods: Case control study, data from medical records of inpatients and 
outpatients in Dr. Kariadi General Hospital from January 2015 to December 2017. 
Results:  Study subject: Two hundred and ten HIV/AIDS patients, were included; 
105 (56.75%) as cases and 105 (9.65%) control patients. The significant risk factors 
for mortality were as follow: male (p =0.030); age ≥ 45 years (p =0.035); non-
compliance to treatment (p =0,000); WHO clinical stage III and IV (p =0,000); co-
infection of pulmonary tuberculosis (p =0,000); CD4 cell count < 200 cells/mm3 (p 
=0,000); eGFR < 60 mL/minute/1.72 m2 (p =0.001) and Hemoglobin level < 10 g/dL 
(p =0.008). The non-significant risk factors for mortality were as follow: level of 
education (p =0.650); Hepatitis B co-infection (p =0.153) and Hepatitis C co-
infection (p =0.506). The most important risk factors for mortality in this study in 
were non-compliance to treatment (p =0.003; OR = 3.285) and CD4 count < 200 
cells/mm3 (p =0.014; OR = 5.480). 
Conclusion: In this study, the risk factors for mortality in HIV/AIDS patients were 
male; age ≥ 45 years; non-compliance to treatment; WHO clinical stage III and IV; 
co-infection of pulmonary tuberculosis, CD4 count < 200 cells/mm3; eGFR < 60 
mL/minute/1.72 m2 and Hb level < 10 g/dL. The most important risk factors for 
mortality were non-compliance to treatment and CD4 count < 200 cells/mm3 
 






Human Immunodeficiency Virus (HIV) is a 
major public health problem worldwide. The high 
incidence and mortality rate of HIV infection and 
Acquired Immune Deficiency Syndrome (AIDS) is 
a global health problem. World Health Organization 
(WHO) estimates that 36.7 million people 
worldwide are living with HIV / AIDS by the end of 
2016.1 Indonesia is reported as one of the Asian 
countries that has experienced a significant increase 
in HIV infection with a number of new infection 
cases of 48,000 cases in 2016 and is ranked third in 
the Asia Pacific after India and China. The Data and 
Information Center of the Ministry of Health of the 
Republic of Indonesia in 2016 stated that until now 
HIV/AIDS has spread in 407 of 507 districts/cities 
(80%) in all provinces in Indonesia. The cumulative 
number of HIV/AIDS cases in Indonesia from 1 
April 1987 to 31 December 2016, namely HIV cases 
of 232,323 cases and AIDS 86,725 cases with a 
death toll of 14,608 cases. Central Java Province 
occupies the fifth position with the cumulative 
number of HIV cases of 14,690 cases and AIDS 
cases of 5,442.2 The number of HIV/AIDS deaths in 
Central Java ranks third after DKI Jakarta and East 
Java Provinces, where from 1987 to March 2017 
there were 1554 deaths with a Case Rate of 12.41%.3 
HIV/AIDS has been one of the greatest challenges 
for decades. Determining the long-term mortality 
rate for HIV/AIDS cases is a challenge in itself.  The 
prognosis of most untreated HIV/AIDS cases is poor 
with an overall mortality   rate > 90% with a mean 
time between infection and death 8-10 years.4 
Research on risk factors for mortality of 
HIV/AIDS patients in Indonesia is still rarely done   
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and especially in Dr. Kariadi General Hospital has 
never been done. Sumantri R, et al in their research 
on important risk factors for mortality in HIV/AIDS 
patients at Dr. Hasan Sadikin General Hospital 
Bandung reported that CD4 count ≤ 50 cells/mm3, 
degree of moderate-severe anemia and Body Mass 
Index (BMI) <18.5 are important risk factors for 
mortality in HIV/AIDS patients.4 
HIV infection will eventually cause a state of 
severe immunosuppression that causes the 
emergence of various AIDS clinical conditions and 
has a negative impact on the quality of life of patients 
and can even lead to death. However, the rate of 
progression of HIV disease among these patients was 
very broad. Identification of risk factors for 
progression of HIV infection to AIDS and even death 
is very important to recognize. This is an effort to 
carry out optimal management and management of 
HIV/AIDS patients so as to reduce the progression 
rate of HIV infection and the mortality rate for AIDS 
patients.5 
The decline in cases of death of HIV/AIDS 
patients in Indonesia has shown good progress and 
proves that the efforts of ARV treatment are 
effective, but research related to risk factors for 
mortality of HIV/AIDS patients is still rare. In an 
effort to plan and evaluate advance ARV therapy 
programs, it is important to know information on risk 
factors for mortality in HIV/AIDS patients. This is 
also one of the strategies to achieve the success of the 
AIDS program and as a step towards achieving the 
Getting to Zero which includes zero new infections, 
zero death from AIDS-related illness and zero 
discrimination which have become Indonesia's 
commitment in the 2007 ASEAN Declaration.6 This 
study tries to find the risk factors for mortality in 
HIV/AIDS patients in Dr. Kariadi General Hospital 
Semarang so that it will increase awareness of these 
risk factors for mortality in maintaining the quality of 
life of HIV/AIDS patients. 
2. Methods 
This research is a case control study. Retrieval 
of data from medical records of inpatients and 
outpatients at Dr. Kariadi General Hospital Semarang 
during the period January 2015 to December 2017. 
The study sample size was 210 HIV/AIDS patients 
consisting of 105 dead and 105 living patients. 
The incoming data is processed manually for re-
checking, coding, tabulation and entered into 
computer data entry for statistical analysis with the 
SPSS program. Univariate analysis was carried out to 
see data on data characteristics and to analyze the 
relationship between each independent variable and 
the dependent variable. The p value is considered 
significant if <0.05. Bivariate analysis using the chi-
square test with Yate correction at Alfa 0.05 which is 
equipped with a risk measure OR (Odd Ratio). 
Multivariate analysis used logistic regression 
analysis which involved all independent variables 
which had p <0.05 in bivariate analysis 
3. Results 
Four hundred and thirty-five inpatients and 837 
new outpatients were including in this study (from 
January 2015 to December 2017). Based on these 
data, 113 inpatients died and 72 outpatients died. 
Sampling of 210 research subjects was carried out on 
inpatient and outpatient medical records which were 
considered quite complete, covering the 11 variables 
studied although not all of these medical records 
provided complete variables. 
In this study, 136 people (64.8%) was male and 
72.4% died. Male is a risk factor for mortality in 
HIV/AIDS patients with a risk of death 1.966 times 
greater than that of women (p =0.030, OR 1.966). 
According to the age category, age <45 years and ≥ 
45 years of study subjects were 160 (76.2%) and 50 
(23.8%) respectively. Research subjects died in the 
age category ≥ 45 years 32 people (30.5%) and the 
age category <45 years 73 people (69.5%). Age ≥ 45 
years is a significant risk factor for mortality in 
HIV/AIDS patients with a risk 2.119 times greater 
than those aged <45 years (p =0.035, OR 2.119). 
Research subjects based on the level of 
education are divided into the level of basic education 
(not in school, primary school, junior high school) 62 
people (29.5%) and advance education level (senior 
high school, college) 148 people (70.5%). The 
number of research subjects died at the basic 
education level of 29 people (27.6%) and the level of 
advance education 76 (72.4%). Education level is not 
a risk factor for mortality in HIV/AIDS patients (p 
=0.650). Based on treatment compliance, the most 
research subjects died due to non-compliance to 
treatment of 59 people (56.2%) and 46 people 
(43.8%) were compliance to treatment. Non-
compliance to treatment was a risk factor for 
mortality in HIV/AIDS patients and had a risk of 
5.805 times greater than that of patients who were 
compliance to treatment (p =0.000, OR 5.805) and in 
multivariate analysis was the most important risk 
factor for the mortality of HIV/AIDS patients (p 
=0.003) 
The research subjects who died most were the 
WHO III and IV clinical stages as many as 105 
people (100%). WHO clinical stages III and IV are 
risk factors for mortality in HIV/AIDS patients (p 
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=0.000) but how much risk for stage III and IV 
patient mortality that occurs cannot be assessed 
because in data collection there were no patients with 
clinical stages I and II who died. Based on the 
presence or absence of pulmonary tuberculosis co-
infection, research subjects died accompanied by 
pulmonary tuberculosis co-infection 48 people 
(45.7%) while without pulmonary tuberculosis co-
infection 57 people (54.3%). Pulmonary tuberculosis 
co-infection is a risk factor for mortality in 
HIV/AIDS patients and a person with pulmonary 
tuberculosis co-infection has a 3.177 times greater 
risk of mortality than someone without pulmonary 
tuberculosis co-infection (p =0.000, OR 3.177). 
The study subjects who died based on the 
presence or absence of Hepatitis B co-infection were 
54 people without Hepatitis B co-infection (51.42%), 
40 people (38.11%) unknown status of Hepatitis B 
co-infection and 11 people with Hepatitis B co-
infection. (10.47%). Hepatitis B co-infection is not a 
risk factor for mortality in HIV/AIDS patients (p 
=0.153). Based on the presence or absence of 
Hepatitis C co-infection, the majority of study 
subjects who died were unknown Hepatitis C co-
infection status with 58 people (55.24%), without 
Hepatitis C co-infection 42 people (40%) and with 
Hepatitis C co-infection 5 people (4.76 %). Hepatitis 
C co-infection was not a risk factor for mortality in 
HIV/AIDS patients (p =0.506). 
The CD4 count of the study subjects who died 
the most were with CD4 counts <200 cells/mm3 82 
people (78.09%) while 4 people with CD4 counts ≥ 
200 cells/mm3 (3.8%). The mean CD4 count of the 
study subjects died was 37.48 cells/mm3. CD4 count 
<200 cells/mm3 is a risk factor for mortality in 
HIV/AIDS patients with a risk of 10.399 times 
greater than a CD4 count ≥ 200 cells/mm3 (p =0.000, 
OR 10.399) and in multivariate analysis it is the most 
important risk factor for mortality in HIV/AIDS 
patients (p =0.014). Based on eGFR, 62 people 
(59%) of the study subjects died with eGFR ≥ 60 
mL/minute/1.72 m2 and 43 people (41%) died with 
eGFR <60 mL/minute/1.72 m2. The mean eGFR of 
the study subjects died was 71.19 mL/minute/1.72 
m2. eGFR <60 mL/minute/1.72 m2 is a risk factor for 
mortality in HIV/AIDS patients with a risk of 3.139 
times greater than eGFR ≥ 60 mL/minute/1.72 m2 (p 
=0.001, OR 3.139). Based on Hb levels, 61 people 
(58.1%) of the study subjects died at Hb levels ≥ 10 
g/dL while 44 people (41.9%) died at Hb levels <10 
g/dL. The average Hb level of the study subjects died 
was 10.51 g/dL. Hb level <10 g/dL is a risk factor for 
mortality in HIV/AIDS patients and has a risk of 
2.308 times greater than Hb level ≥ 10 g/dL (p 
=0.008, OR 2.308). 
The results of the chi-square test analysis 
showed that there were 8 variables which were 
significant as risk factors for the mortality of 
HIV/AIDS patients in Dr. Kariadi General Hospital 
Semarang, namely male, age ≥ 45 years, treatment 
non-compliance, WHO III and IV clinical stages, 
pulmonary tuberculosis co-infection, CD4 count 
<200 cells/mm3, eGFR <60 mL/minute/1.72 m2 and 
Hb <10 g/dL while the level of education, hepatitis B 
co-infection and hepatitis C co-infection were not 
significant risk factors for the mortality of HIV/AIDS 
patients in Dr. Kariadi General Hospital Semarang as 
depicted in Table 1.  
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Multivariate analysis using logistic regression 
test. Based on the results of the chi-square test, 
variables having p <0.05 were included in the 
multivariate analysis. These variables include male (p 
=0.030), age ≥ 45 years (p =0.035), non-compliance 
with treatment (p =0.000), WHO III and IV clinical 
stages (p =0.000), pulmonary tuberculosis co-
infection (p =0,000), CD4 count <200 cells/mm3 (p 
=0,000), eGFR <60 mL/minute/1.72 m2 (p =0.001) 
=0.08). After multivariate analysis, 2 variables 
showed p value <0.05, namely non-compliance to 
treatment (p =0.003) and CD4 count <200 cells / mm3 
(p =0.014), which are the most significant risk factors 
for mortality in HIV/AIDS patients at Dr. Kariadi 
General Hospital Semarang. The complete data is 






Median Mean OR p* 
Demographic Characteristics 
Sex 
Male 76(72.4%) 60(57.1%)   1.966 0.030 




Age (year)   35    
<45 73(69.5%) 87(82.9%)     
≥45 32(30.5%) 18(17.1%)   2.119 0.035 
Social Characteristics 
 Level of Education 
Basic  
 
29(27.6%) 33(31.4%)   0.833 0.650 
Advance  76(72.4%) 72(68.6%)     
Treatment Compliance 
 Yes    46(43.8%) 86(81.9%)     
No    59(56.2%) 19(18.1%)   5.805 0.000 
Clinical Characteristics 
WHO Clinical Stage III and IV 
Yes  105(100%) 56(53.3%)   - 0.000 
No    0(0%) 49(46.7%)     
Pulmonary Tb Co-infection 
Yes    48(45.7%)    22(21%)      3.177 0.000 
No    57(54.3%)    83(79%)     
Hepatitis B Co-infection 
Yes 11(16.9%)    5(7.4%)      2.567   0.153 
No 
 
54(83.1%)    63(92.6%)     
Hepatitis C Co-infection 
Yes    5(10.6%)    2(4.7%)      2.440 0.506 
No    42(89.4%)  41(95.3%)     
CD4 Count (cell/mm3)   103.73   
<200    82(95.3%)   69(66.3%)    10.399 0.000 
≥200    4(4.7%)   35(33.7%)     
eGFR (mL/minute/1.72 m2 )   80.42   
<60 43(41%) 19(18.1%)     3.139 0.001 
≥60 62(59%) 86(81.9%)     
Hb Level (g/dL)   11.0   
<10 44(41.9%) 25(23.8%)     2.308 0.008 
≥10 61(58.1%) 80(76.2%)     
*Chi-square test 
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Table 2. Multivariate Analysis of Risk Factors for 
Mortality in HIV/AIDS Patients 
No Variable  OR     p 
1 Male 2.074 0.105 
2 Age ≥ 45 years 1.347 0.531 
3 Non-compliance to 
treatment 
3.285 0.003 







6 CD4 count < 200 
cell/mm3 
5.480 0.014 
7 eGFR < 60 
mL/minute/1.72 m2 
1.949 0.126 
8 Hb level < 10 g/dL 1.625 0.270 
 Constant 0.000 0.996 
 
4. Discussion 
The number of HIV/AIDS patients in this study 
was based on gender according to data from the 
Directorate General of Disease Prevention and 
Control of the Ministry of Health of the Republic of 
Indonesia in 2017 which stated that there were more 
males than females based on data from 1987-2017, 
namely men amounting to 56.5%, female 31.6% 
while 11.8% did not report gender. This is related to 
sexual intercourse (heterosexual) which is the main 
transmission of HIV transmission, where 
transmission through heterosexual intercourse is 
more common in the male sex.3 Male is a risk factor 
for mortality in HIV/AIDS patients with a risk of 
death 1.966 times greater than that of women (p 
=0.030, OR 1.966). This is in accordance with the 
research of Gunda W, et al in 2017 which stated that 
male is a risk factor for the mortality of HIV/AIDS 
patients.7 Biological differences between gender, 
such as the effect of sex hormones on immunity, 
greatly influence the progression of HIV infection. 
The immune system of men and women is the same 
before the reproductive period, but begins to differ 
when they enter reproductive age. Female when they 
enter the reproductive period are more immune to 
infection. This is caused by the production of the 
female hormone estrogen which affects the increased 
synthesis of IgG and IgA. 17β-estradiol (E2) which is 
the main and most potent estrogen in female works 
by binding to estrogen receptors (ER) in the 
reproductive tract tissue and in immune cells in 
peripheral blood, including CD4 T cells and 
macrophages which are 2 target cells primary HIV so 
E2 has antiviral properties against HIV. E2 acts 
directly on CD4 T cells and macrophages to inhibit 
HIV replication.8,9,10  
The number of HIV/AIDS patients based on age 
in this study is according to data from the Directorate 
General of Disease Prevention and Control of the 
Ministry of Health of the Republic of Indonesia in 
2017 which states that most occur in the age group of 
20-29 years (31.4%) followed by 30-39 years ( 
30.6%) and 40-49 years old (12.8%).3 Age <45 years 
is the group most infected with HIV because it is 
associated with active sex, which is the main 
transmission of HIV transmission.11 Age ≥ 45 years 
is a significant risk factor for mortality in HIV/AIDS 
patients with a risk of 2.119 times greater than those 
aged <45 years (p =0.035, OR 2.119). This is in 
accordance with the research of Rubaihayo, et al in 
2015 which stated that age ≥ 45 years is a strong risk 
factor for the mortality of HIV/AIDS patients.12 
Zheng, et al in 2014 stated that if the age> 45 years 
have a greater risk of mortality than those aged 18-29 
years.13 The age limit of <45 years and ≥ 45 years is 
based on the fact that at ≥ 45 years of age there is a 
thymus involution where the thymus volume is 
significantly smaller compared to young age. The 
thymus is an important organ in the development of 
the immune system and has a primary function as a 
site for T lymphocyte maturation.14 Increasing age is 
associated with decreased immune and physiological 
function. The immune system matures in adulthood 
and declines again at old age.11 Older age is a strong 
risk factor in accelerating the progression of HIV 
infection and increasing AIDS-related mortality.15   
Non-compliance to treatment was one of the 
most important risk factors for mortality in 
HIV/AIDS patients in this study. Research subjects 
died more in research subjects who were non-
compliance to treatment. Non-compliance to 
treatment was a risk factor for mortality in HIV/AIDS 
patients and had a risk of 5.805 times greater than that 
of patients who were compliance to treatment (p 
=0.000, OR 5.805) and in multivariate analysis was 
the most important risk factor for the mortality of 
HIV/AIDS patients (p =0.003). This is consistent 
with a study by Stringer, et al in 2008 which stated 
that non-compliance was a risk factor for mortality 
during the use of ARV.16 Research by Ayalew, et al 
in 2017 states that non-compliance to taking ARV is 
a risk factor for mortality in HIV/AIDS patients 
where non-compliance to ARV causes treatment 
failure with an increase in the occurrence of 
mutations that can lead to HIV resistance to ARV and 
eventually lead to death.17 Non-compliance to 
treatment is an important factor for treatment failure 
in HIV/AIDS patients where there is a significant 
relationship between non-compliance to taking 
medication with failure of HIV suppression, 
increased HIV resistance, decreased CD4 cell counts 
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and decreased expectations and quality of life.18 
WHO clinical stages III and IV are risk factors for 
mortality of HIV/AIDS patients in this study. This is 
in accordance with research by Gunda W, et al in 
2017 and by Utami, et al in 2015 which stated that the 
WHO clinical stages III and IV were risk factors for 
the mortality of HIV/AIDS patients.7,19 Clinical 
stages III and IV have a more severe clinical picture 
than clinical stages I and II.6 The clinical stage of 
HIV/AIDS is strongly influenced by the CD4 count. 
CD4 count <200 cells/mm3 will increase the risk for 
opportunistic infections. The lower CD4 cell count, 
the more and more opportunistic infections will 
occur, causing the clinical stage of HIV/AIDS to 
become increasingly severe.20 HIV/AIDS clinical 
stage, treatment compliance and CD4 count are 
variables that are strongly interrelated and cannot be 
separated. Non-compliance to ARV will reduce CD4 
counts, which in turn can lead to opportunistic 
infections, which will aggravate the clinical stage of 
HIV/AIDS and increase mortality. 
Pulmonary tuberculosis co-infection was a risk 
factor for the mortality of HIV/AIDS patients in this 
study and someone with pulmonary tuberculosis co-
infection had a 3.177 times greater risk of mortality 
than someone without pulmonary tuberculosis co-
infection (p =0.000, OR 3.177). This is consistent 
with research by Rajagopalan N, et al in 2009 and by 
Hamidi O, et al in 2017 which stated that pulmonary 
tuberculosis co-infection is a risk factor for mortality 
in HIV/AIDS patients.21,22 Pulmonary tuberculosis is 
the most common cause of death for HIV/AIDS 
patients. The risk of death for HIV-infected persons 
with pulmonary tuberculosis co-infection is twice 
that of those without pulmonary tuberculosis co-
infection.23 Patients with pulmonary tuberculosis co-
infection are included in clinical stage III so that the 
relationship between pulmonary tuberculosis co-
infection, clinical stage III, non-compliance to 
treatment and CD4 count <200 cells /mm3 are closely 
related. Research by Kumar, et al in 2017 stated that 
a mean CD4 count of 74.5 cells/mm3 would increase 
the risk of pulmonary tuberculosis co-infection in 
someone with HIV infection.24 CD4 is the best 
parameter for measuring immunodeficiency. CD4 
count <200 cells/mm3 in this study was a risk factor 
for mortality in HIV/AIDS patients with a risk of 
10.399 times greater than a CD4 count ≥ 200 
cells/mm3 (p =0.000 OR 10.399) and in the 
multivariate analysis was the most important risk 
factor for mortality in HIV/AIDS patients (p =0.014). 
This is consistent with research by Gunda W, et al in 
2017, Chen L, et al in 2017 and Garriga C, et al in 
2015 which stated that CD4 <200 cells/mm3 was a 
risk factor for mortality in HIV/AIDS patients.26,7,27 
CD4 count is closely related to treatment compliance. 
This can be seen in the results of this study, where the 
2 variables that played the most role as risk factors 
for mortality in HIV/AIDS patients were non-
compliance to treatment and CD4 count <200 
cells/mm3. Non-compliance to ARV results in lower 
CD4 cell counts whereas ARV therapy has been 
shown to reduce viral load, increase CD4 cell count, 
improve quality of life, reduce opportunistic 
infections and thus reduce morbidity and mortality.25 
CD4 cell count is an important prognostic indicator 
of remaining levels of immune function.28 CD4 cells 
are an early indication of disease progression because 
CD4 counts have decreased before clinical 
conditions.25 CD4 count is the single best laboratory 
parameter for determining the clinical outcome of 
HIV/AIDS patients. CD4 count strongly predicted 
HIV infection progression, risk of opportunistic 
infections and short-term death. Lower CD4 counts 
correlate with an increased risk of morbidity and 
mortality in HIV/AIDS patients. CD4 count <200 
cells/mm3 was defined as the lower threshold for 
severe opportunistic infections in general.28  
eGFR <60 mL/minute/1.72 m2 in this study was 
a risk factor for mortality in HIV/AIDS patients with 
a risk of 3.139 times greater than eGFR ≥ 60 
mL/minute/1.72 m2 (p =0.001, OR 3.139). This is 
consistent with research by Kim J, et al in 2017 which 
stated that eGFR <60 mL/minute/1.72 m2 is a risk 
factor for mortality in HIV/AIDS patients.29 eGFR of 
someone infected with HIV is an accurate marker that 
is useful in diagnosing HIVAN and other glomerular 
diseases early and identify patients at high risk for 
rapid kidney function decline which will lead to an 
increased risk of cardiovascular disease. Kidney 
disease remains a significant cause of morbidity and 
mortality. Kidney disease is known as a complication 
of HIV and has an important role in the mortality of 
HIV/AIDS patients.30 Anemia is the most common 
hematological disorder in HIV/AIDS patients in 
Indonesia and is associated with HIV disease 
progression and poor clinical outcomes.31 
Hemoglobin level <10 g/dL was a risk factor for 
mortality in HIV/AIDS patients in this study and had 
a risk of 2.308 times greater than Hb levels ≥ 10 g/dL 
(p =0.008, OR 2.308). This is in accordance with 
research by Damtew et al in 2015 which stated that 
Hemoglobin <10 g/dL was a risk factor for mortality 
in HIV/AIDS patients.32 Hemoglobin level reflects 
the speed of disease progression and can predict the 
prognosis of a disease. A decrease in Hb levels 
correlates with a decrease in CD4 counts, so in this 
study there is a close relationship between Hb levels 
and CD4 counts.33 CD4 count <200 cells/mm3 and 
non-compliance to treatment as previously 
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mentioned were the most significant risk factors for 
mortality in HIV/AIDS patients in this study so that 
someone who was not compliance to treatment would 
cause a decrease in CD4 counts which eventually led 
to a decrease in Hb levels. Some opinions state that 
an increase in Hb levels can predict the success of 
therapy so that someone who is compliance to 
treatment will increase the CD4 count and Hb level 
which ultimately leads to success of therapy and 
reduces mortality. Anemia is associated with the 
progression of AIDS and with shorter survival of 
HIV/AIDS patients. Anemia in HIV/AIDS is a 
marker of progression of HIV disease because it is 
one of the clinical features of most opportunistic 
infections. This occurs due to micronutrient 
deficiency and impaired erythropoietin production. 
In addition, various drugs used by HIV patients also 
play a role in the onset of anemia, for example 
Zidovudine. Anemia causes hypoxia in which the 
blood's ability to bind oxygen is reduced due to the 
reduced number of hemoglobin molecules. Anemia 
in severe infection causes tissue hypoxia which can 
progress to multi-organ failure leading to mortality.33 
The level of education in this study is divided 
into the level of basic education (no school, 
elementary, junior high school) and advanced 
education level (senior high school and college). 
Most of the patients who died were patients with 
advanced education level of 76 people (72.4%) while 
29 people (27.6%) had a basic education level with a 
p value of 0.650 so that the level of primary education 
was not a risk factor for mortality in HIV/AIDS 
patients. This is consistent with research by Bhatta, et 
al in 2013 and research by Okonkwo, et al in 2014 
which did not have a relationship between the level 
of primary education and mortality.34 The absence of 
a relationship between education level and mortality 
in this study can be attributed to the condition that 
most (70.5%) of the sample of this study were 
dominated by advanced education levels (senior high 
school and college). This can occur because 
individuals with low basic education have low 
awareness of access to health services and medical 
care so they do not seek health services if they are 
sick.35   
HIV-Hepatitis B co-infection has a high 
prevalence. The relationship of Hepatitis B co-
infection with HIV/AIDS patient mortality is still 
controversial.36 All people living with HIV must 
undergo routine HBsAg examinations to detect early 
hepatitis B co-infection. Based on the data of this 
study, not all HIV/AIDS patients in Dr. Kariadi 
General Hospital Semarang routinely performed 
Hepatitis B screening tests. Hepatitis B screening 
examinations were only performed on 133 patients 
(63.33%). Based on these data, only 11 patients 
(10.47%) with hepatitis B co-infection died while 54 
patients (51.42%) died without hepatitis B co-
infection. The results of this study were that hepatitis 
B co-infection was not a risk factor for HIV/AIDS 
patient mortality (p =0.153). This is consistent with 
research by Knapp, et al in 2013 which stated that 
there was no difference in life expectancy between 
HIV/AIDS positive and negative HBsAg patients and 
research by Rockstroh in 2006 which stated that 
Hepatitis B co-infection was not a risk factor for 
mortality in HIV/AIDS patients.37,38 Research from 
the Multicenter AIDS Cohort Study (MACS) also 
states that there is no relationship between Hepatitis 
B co-infection and the mortality of HIV/AIDS 
patients.37 Some of the reasons why Hepatitis B co-
infection was not a risk factor for the mortality of 
HIV/AIDS patients in this study were that there were 
still many HIV/AIDS patients who had not 
undergone routine HBsAg examinations, namely 77 
people (36.66%). Another thing is that all the subjects 
of this study have received ARV HIV/AIDS therapy 
where this ARV therapy reduces the progression of 
liver disease in HIV/AIDS patients with Hepatitis B 
co-infection, thereby reducing mortality.25 The 
mortality risk of HIV patients with hepatitis B co-
infection is 3 times greater than that of HIV patients 
without hepatitis B co-infection and occurs when the 
hepatitis B infection has caused liver cirrhosis or 
complications of portal hypertension have occurred. 
Cirrhosis of the liver and its complications is a strong 
risk factor for mortality in HIV patients co-infected 
with Hepatitis B.39 
Patients infected with HIV/AIDS should be 
screened for Hepatitis C virus infection. Initial 
screening for Hepatitis C is carried out with anti-
HCV testing.40 Co-infection of HIV with Hepatitis C 
can affect the natural course of the Hepatitis C virus. 
Hepatitis C screening tests should be carried out 
routinely in all HIV/AIDS patients, especially in 
preparation for ARV administration.25 Based on this 
research data, there are still many HIV/AIDS patients 
in Dr. Kariadi General Hospital who has not been 
routinely tested for Anti HCV. Only 90 patients 
(42.85%) were tested for Anti HCV. Based on this 
number, 5 patients (4.76%) died with Hepatitis C co-
infection while 42 patients (40%) died without 
Hepatitis C co-infection. The results of this study 
indicate that Hepatitis C co-infection is not a risk 
factor for mortality in HIV/AIDS patients (p. = 
0.506). This is consistent with a study by Rockstroh 
in 2006 which stated that Hepatitis C co-infection is 
not a risk factor for the mortality of HIV/AIDS 
patients.38 Several reasons that Hepatitis C co-
infection was not a risk factor for the mortality of 
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HIV/AIDS patients in this study were that there were 
still many samples of the study that had not been 
subjected to routine anti-HCV examinations, namely 
120 people (57.14%). The provision of ARV for 
HIV/AIDS patients was also related to this, where all 
research subjects in this study had received ARV 
HIV/AIDS therapy. Administration of ARVs in 
HIV/AIDS patients with Hepatitis C co-infection will 
slow the progression of liver fibrosis, reduce liver 
inflammation and reduce the risk of liver-related 
death in Hepatitis C co-infected patients.40 Immune 
restorations with ARV therapy has an important 
effect in reducing the risk of mortality in patients 
coinfected with Hepatitis C. Therefore, HIV/AIDS 
patients coinfected with Hepatitis C are 
recommended to be given ARV earlier than 
HIV/AIDS patients without Hepatitis C co-
infection.41 
Multivariate analysis showed that the most 
significant risk factors for mortality in HIV/AIDS 
patients were non-compliance to treatment and a CD4 
count <200 cells/mm3. This is consistent with 
research by Ayalew, et al in 2017 which stated that 
the risk factors for mortality that most played a role 
in HIV/AIDS patients were non-compliance with 
treatment and low CD4 counts.17 The two risk factors 
for mortality have a strong relationship. Non-
compliance to ARV therapy results in lower CD4 
counts where ARV therapy has been shown to reduce 
viral load counts, increase CD4 cell counts, improve 
quality of life, reduce opportunistic infections and 
thus reduce morbidity and mortality.25 Non-
compliance to treatment in this case was defined as 
taking ARV <95% of the dose within a month. Non-
compliance to treatment and CD4 count <200 
cells/mm3 also had an effect on other significant 
mortality risk factors, including male gender, age ≥ 
45 years, WHO III and IV clinical stages, pulmonary 
tuberculosis co-infection, eGFR <60 mL/minute/1.73 
m2 and Hb content <10 g/dL. Non-compliance to 
treatment was more common in the male sex, which 
would cause a low CD4 count. Older age, in this case 
age ≥ 45 years, is a risk factor for treatment non-
compliance which ultimately leads to a lower CD4 
count. Non-compliance to treatment and CD4 count 
<200 cells/mm3 had a strong association with WHO 
III and IV clinical stages. CD4 count <200 cells/mm3 
is a risk factor for the emergence of opportunistic 
infections and co-infection at the WHO III and IV 
clinical stages. The lower the CD4 count, the heavier 
and more opportunistic infections and co-infections 
will occur. One of the co-infections that are often 
found at WHO clinical stage III is pulmonary 
tuberculosis. An average CD4 count of 74.5 
cells/mm3 will increase the risk of pulmonary 
tuberculosis co-infection in HIV/AIDS patient.24  
eGFR <60 mL/minute/1.73m2 is a risk factor for 
increased cardiovascular events in HIV/AIDS 
patients which will increase the risk of mortality. This 
is associated with a low CD4 count. A low CD4 count 
increases the risk of developing renal insufficiency.29 
A decrease in Hb levels correlates with a decrease in 
CD4 counts so that non-compliance to treatment will 
lead to a decrease in CD4 counts which will 
eventually lead to a decrease in Hb levels.33    
5. Conclusion 
Risk factors for mortality in HIV/AIDS patients 
include male gender, age ≥ 45 years, non-compliance 
to treatment, WHO III and IV clinical stages, 
pulmonary tuberculosis co-infection, CD4 count 
<200 cells/mm3, eGFR <60 mL/minute/1,72 m2 and 
Hb content <10 g/dL. The risk factors for mortality 
that played the most role were non-compliance to 
treatment and a CD4 count <200 cells/mm3. 
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